CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA
CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA of 200 µg.
| Target | CML-HSA/Nε-(Carboxymethyl)lysine |
|---|---|
| Product Type | Recombinant Protein |
| Formulation | The CML-HSA /Nε-(carboxymethyl) lysine-HSA is supplied frozen in a buffer containing 10mM PBS (pH 7.2). |
| Research Area | Metabolism |
| Description/Background | Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported (1, 2), it was demonstrated that Nε -(Carboxymethyl)lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3–5), retinopathy (6), and atherosclerosis (7–9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10). |
| Storage Temperature | -20°C |
| Concentration | 1.0 mg/mL |
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
Related Products
Related Content
![Brochure: Knockout Antibodies [KO] validation](https://products.mblintl.com/wp-content/uploads/2024/07/Knock-out-Antibodies-Flyer-Image-610x675-1.jpg)
